Headlines about Biohaven Pharmaceutical (NYSE:BHVN) have trended positive on Tuesday, according to Accern. Accern identifies positive and negative press coverage by analyzing more than 20 million blog and news sources in real-time. Accern ranks coverage of companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Biohaven Pharmaceutical earned a news impact score of 0.26 on Accern’s scale. Accern also gave news articles about the company an impact score of 45.3698545684344 out of 100, indicating that recent press coverage is somewhat unlikely to have an impact on the company’s share price in the next few days.
These are some of the media stories that may have effected Accern’s scoring:
- Kleo Pharmaceuticals Inc. Appoints Luca Rastelli, PhD as Chief Scientific Officer (finance.yahoo.com)
- Biohaven Pharmaceutical (BHVN) Presents At Needham And Company 17th Annual Healthcare Conference – Slideshow (seekingalpha.com)
- Biohaven Pharmaceutical Holding Co Ltd (BHVN) Receives Average Recommendation of “Buy” from Analysts (americanbankingnews.com)
- Canaccord Sees An ‘Intriguing Setup’ In Biohaven Following Reaction To Phase 3 News (msn.com)
- Biohaven Pharmaceutical Target of Unusually High Options Trading (BHVN) (americanbankingnews.com)
NYSE BHVN traded up $0.57 during mid-day trading on Tuesday, hitting $25.10. The stock had a trading volume of 760,076 shares, compared to its average volume of 774,895. Biohaven Pharmaceutical has a twelve month low of $16.50 and a twelve month high of $39.51. The company has a market cap of $927.81 and a P/E ratio of -5.02.
In other Biohaven Pharmaceutical news, insider Robert Berman sold 35,000 shares of the firm’s stock in a transaction on Wednesday, January 10th. The stock was sold at an average price of $27.52, for a total value of $963,200.00. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, major shareholder Portage Biotech Inc. sold 35,650 shares of the firm’s stock in a transaction on Wednesday, January 3rd. The stock was sold at an average price of $28.61, for a total value of $1,019,946.50. Following the completion of the sale, the insider now directly owns 124,371 shares of the company’s stock, valued at $3,558,254.31. The disclosure for this sale can be found here. Insiders sold a total of 783,546 shares of company stock valued at $22,591,021 over the last ninety days.
TRADEMARK VIOLATION WARNING: This report was originally published by BBNS and is owned by of BBNS. If you are viewing this report on another website, it was illegally stolen and republished in violation of US and international trademark & copyright laws. The original version of this report can be accessed at https://baseballnewssource.com/2018/04/03/favorable-press-coverage-somewhat-unlikely-to-affect-biohaven-pharmaceutical-bhvn-stock-price/2018465.html.
About Biohaven Pharmaceutical
Biohaven Pharmaceutical Holding Company Ltd. is a United States-based biopharmaceutical company. The Company is engaged in the identification and development of clinical-stage compounds targeting orphan neurologic indications and other neurological pathways. It has a portfolio of multiple late-stage drug candidates.
Receive News & Ratings for Biohaven Pharmaceutical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Biohaven Pharmaceutical and related companies with MarketBeat.com's FREE daily email newsletter.